| Ol (lots) | Call Price | Strike Price | Put Price | Ol (lots) |
|---|---|---|---|---|
| - | - | 4,300 | ₹4.4 -27.27% | 3,2500% |
| - | - | 4,400 | ₹7 0% | 9,7500% |
| - | - | 4,450 | ₹11.95 0% | 5,5000% |
| - | - | 4,500 | ₹7.95 0% | 5,8750% |
| - | - | 4,550 | ₹14.75 -4.22% | 2,8750% |
| 3750% | ₹633.1 0% | 4,600 | ₹10 8.69% | 6,1250% |
| 00% | ₹592.45 0% | 4,650 | ₹18.25 0% | 9,7500% |
| - | - | 4,700 | ₹15.45 14.44% | 8,75012.90% |
| 00% | ₹498.9 0% | 4,750 | ₹19.3 13.52% | 1,6258.33% |
| 2500% | ₹279.6 0% | 4,800 | ₹24.65 14.91% | 6,375-1.92% |
| 1250% | ₹305.6 0% | 4,850 | ₹49.45 -5.35% | 1,2500% |
| 1,1250% | ₹340.2 0% | 4,900 | ₹36.85 9.18% | 14,000-5.88% |
| 5,5000% | ₹183.5 0% | 4,950 | ₹41.8 -3.01% | 8,2500% |
| 11,8750% | ₹300.85 0% | 5,000 | ₹61.35 17.19% | 39,5000% |
| 4,8750% | ₹280 0% | 5,050 | ₹72.15 3.73% | 13,625-6.83% |
| 23,375-1.57% | ₹173.3 -15.29% | 5,100 | ₹94.5 14.06% | 27,375-3.52% |
| - | - | 5,150 | ₹114.9 15.7% | 2,2505.88% |
| 44,750-1.91% | ₹120.45 -16.61% | 5,200 | ₹140.1 11.81% | 14,2509.61% |
| 6,87510% | ₹103.1 -16.92% | 5,250 | ₹168.3 14.37% | 7,000-17.64% |
| 77,1250.16% | ₹81.3 -20.41% | 5,300 | ₹173.45 -0.6% | 2,2500% |
| 3,8750% | ₹82.45 -0.84% | 5,350 | - | - |
| 10,250-7.86% | ₹52.1 -23.15% | 5,400 | ₹400 0% | 1250% |
| 6,87512.24% | ₹41.4 -24.31% | 5,450 | ₹500 0% | 2500% |
| 21,2504.29% | ₹33.7 -24.26% | 5,500 | ₹478.1 0% | 3750% |
| 1,5000% | ₹36.15 -0.41% | 5,550 | - | - |
| 12,1254.30% | ₹20.7 -27.87% | 5,600 | - | - |
| 2,6250% | ₹22.35 -2.4% | 5,650 | ₹548 0% | 1250% |
| 9,125-1.35% | ₹14.3 -23.52% | 5,700 | ₹464.6 0% | 3750% |
| 6250% | ₹10.6 0% | 5,750 | - | - |
| 7,375103.44% | ₹9.45 -23.17% | 5,800 | ₹474.55 0% | 1250% |
| - | - | 5,850 | ₹685.45 0% | 3750% |
| 2,1250% | ₹5.25 -17.32% | 6,000 | - | - |
| 6250% | ₹4.85 0% | 6,100 | ₹1,067.1 0% | 1250% |
| 2,125142.85% | ₹2.2 -38.02% | 6,200 | - | - |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
